Skip to main content

Xencor Inc

corporate_fare Company Profile

Xencor Inc

XNCR·NASDAQ·Life Sciences·CIK 0001326732

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for patients with cancer and autoimmune diseases who have unmet medical needs. The company utilizes its protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties and multi-target mechanisms of action. Xencor advances these candidates into clinical-stage development, conducting Phase 1 and Phase 2 studies for a broad portfolio of programs. The company's protein design approach involves engineering Fc domains, which are parts of antibodies that interact with the immune system and control antibody structure. These engineered Fc domains, which are constant and interchangeable across antibodies, provide specific features such as bispecific structure and extended half-life, serving as scaffolds for XmAb drug candidates. Xencor and its partners develop XmAb antibodies and other biotherapeutic drug candidates with improved properties and functionality. Applications of their protein engineering technologies include multi-specific antibodies that engage two or more targets simultaneously, enhancing antibody performance by increasing immune inhibitory activity, improving cytotoxicity, extending circulating half-life, and stabilizing novel protein structures. Three marketed medicines have been developed using Xencor's XmAb protein engineering technologies. The company's modular approach to protein engineering allows for the design of multiple XmAb drug candidates with distinct and novel mechanisms of action. Xencor's business, research, and clinical efforts are focused on developing and advancing a portfolio of XmAb drug candidates in oncology and autoimmune diseases.

Xencor Inc (NASDAQ:XNCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for XNCR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Xencor Reports Strong Cash Position and Outlines Key 2026 Pipeline Milestones

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$125.58M
Net Income
-$91.92M
Diluted EPS
-$1.24
Op. Cash Flow
-$135.12M
Free Cash Flow
-$138.27M
Operating Income
-$177.5M
Cash & Equivalents
$54.07M
Total Debt
$119.75M
Debt / Equity
0.19×
Net Margin
-73.2%
Shares Outstanding
71.87M sh
Source: 10-K · filed 2026-02-25 · accession 0001326732-26-000015
$33.24 -0.06% today
52-week range · as of 2026-11-04 $10.38 – $35.05
Market cap
$2.5B
Volume
1.2M (0.8× avg)
3-mo avg 1.6M
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed XNCR - Filings & News (Page 2)

XNCR
Jan 08, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.95
Real-time Price: $33.24 info
Change: +$18.29 (+122%) info
Market Cap: $2.496B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets